Two Sigma Advisers’s Tvardi Therapeutics TVRD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-16,393
| Closed | -$249K | – | 2596 |
|
|
2025
Q1 | $249K | Sell |
16,393
-5,000
| -23% | -$75.5K | ﹤0.01% | 2055 |
|
|
2024
Q4 | $393K | Sell |
21,393
-2,671
| -11% | -$29.1K | ﹤0.01% | 1870 |
|
|
2024
Q3 | $267K | Buy |
24,064
+131
| +0.5% | +$1.54K | ﹤0.01% | 1961 |
|
|
2024
Q2 | $222K | Buy |
23,933
+5,602
| +31% | +$134K | ﹤0.01% | 2175 |
|
|
2024
Q1 | $601K | Buy |
18,331
+4,048
| +28% | +$105K | ﹤0.01% | 1798 |
|
|
2023
Q4 | $382K | Buy |
14,283
+10,466
| +274% | +$433K | ﹤0.01% | 2026 |
|
|
2023
Q3 | $231K | Buy |
3,817
+256
| +7% | +$24K | ﹤0.01% | 2061 |
|
|
2023
Q2 | $363K | Buy |
3,561
+2,842
| +395% | +$391K | ﹤0.01% | 1923 |
|
|
2023
Q1 | $127K | Buy |
+719
| New | +$241K | ﹤0.01% | 2344 |
|
|
2022
Q3 | – | Sell |
-472
| Closed | -$155K | – | 2766 |
|
|
2022
Q2 | $155K | Sell |
472
-20
| -4% | -$7.02K | ﹤0.01% | 2328 |
|
|
2022
Q1 | $215K | Buy |
+492
| New | +$202K | ﹤0.01% | 2361 |
|
|
2021
Q4 | – | Sell |
-1,892
| Closed | -$1.05M | – | 2836 |
|
|
2021
Q3 | $1.05M | Sell |
1,892
-5,483
| -74% | -$2.75M | ﹤0.01% | 1596 |
|
|
2021
Q2 | $3.79M | Sell |
7,375
-3,117
| -30% | -$1.98M | 0.01% | 991 |
|
|
2021
Q1 | $8.2M | Buy |
10,492
+3,073
| +41% | +$2.1M | 0.02% | 646 |
|
|
2020
Q4 | $4.04M | Buy |
7,419
+822
| +12% | +$431K | 0.01% | 913 |
|
|
2020
Q3 | $3.02M | Buy |
6,597
+3,836
| +139% | +$2.23M | 0.01% | 955 |
|
|
2020
Q2 | $1.7M | Buy |
2,761
+2,136
| +342% | +$1.18M | 0.01% | 1285 |
|
|
2020
Q1 | $297K | Buy |
625
+42
| +7% | +$22.8K | ﹤0.01% | 2016 |
|
|
2019
Q4 | $338K | Buy |
583
+191
| +49% | +$134K | ﹤0.01% | 2022 |
|
|
2019
Q3 | $258K | Buy |
+392
| New | +$326K | ﹤0.01% | 1971 |
|
|
2019
Q2 | – | Sell |
-1,036
| Closed | -$732K | – | 2471 |
|
|
2019
Q1 | $732K | Sell |
1,036
-64
| -6% | -$38.3K | ﹤0.01% | 1641 |
|
|
2018
Q4 | $515K | Buy |
1,100
+575
| +110% | +$371K | ﹤0.01% | 1758 |
|
|
2018
Q3 | $453K | Buy |
+525
| New | +$379K | ﹤0.01% | 1833 |
|
|
2018
Q1 | – | Sell |
-450
| Closed | -$198K | – | 2442 |
|
|
2017
Q4 | $198K | Sell |
450
-25
| -5% | -$11.4K | ﹤0.01% | 2089 |
|
|
2017
Q3 | $234K | Buy |
475
+86
| +22% | +$43.1K | ﹤0.01% | 2007 |
|
|
2017
Q2 | $215K | Buy |
+389
| New | +$247K | ﹤0.01% | 2099 |
|
|
2016
Q2 | – | Sell |
-411
| Closed | -$92K | – | 2221 |
|
|
2016
Q1 | $92K | Buy |
+411
| New | +$123K | ﹤0.01% | 1946 |
|
|
2015
Q4 | – | Sell |
-519
| Closed | -$273K | – | 2049 |
|
|
2015
Q3 | $273K | Buy |
+519
| New | +$347K | ﹤0.01% | 1537 |
|
Other funds holding TVRD
SPC
6CM
FCM
Two Sigma Advisers's TVRD Position: Q2 2025 in Review
Two Sigma Advisers sold out of Tvardi Therapeutics (TVRD) in Q2 2025, closing a stake of 16,393 shares — an estimated $249K sold.
Two Sigma Advisers first reported a position in TVRD in Q3 2015 and held it in 28 quarters. The position peaked at $8.2M in Q1 2021. 56 funds tracked by Wall St. Rank hold TVRD as of Q2 2025.
- Two Sigma Advisers reported no remaining Tvardi Therapeutics position as of Q2 2025 after selling out during the quarter.
- Two Sigma Advisers sold 16,393 Tvardi Therapeutics shares in Q2 2025, an estimated $249K.
- Two Sigma Advisers first reported a position in Tvardi Therapeutics in Q3 2015 and held it in 28 quarters.
- Two Sigma Advisers's Tvardi Therapeutics position peaked at $8.2M in Q1 2021.
- 56 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2025.
Based on Two Sigma Advisers's 13F filing for Q2 2025, filed 14 Aug 2025.